How PD-L1 and NLRP3 signaling in tumors can block PD-1 immunotherapy
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
This work looks at whether blocking a tumor's NLRP3 signaling can help people with melanoma and other cancers get more benefit from anti-PD-1 immunotherapy.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11045849 on NIH RePORTER |
What this research studies
This project explains how a tumor's PD-L1 protein turns on an internal NLRP3 inflammasome that brings in immune-suppressing myeloid cells and quiets CD8 T cells inside the tumor. Researchers use laboratory models and patient tumor samples to show that NLRP3 activity causes resistance to anti-PD-1 drugs and that drugs blocking NLRP3 can restore immune attack in animal models. They have found that some patients' melanomas with extra NLRP3 activity were less likely to respond to PD-1 therapy, and the team will study this link more closely. The aim is to define who might benefit and to support testing NLRP3 inhibitors together with PD-1 blockers in future clinical trials.
Who could benefit from this research
Good fit: Ideal candidates would be people with melanoma (stage III or IV) or other cancers that are not responding to anti-PD-1 therapy and whose tumors show high NLRP3 activity or related genetic changes.
Not a fit: Patients whose tumors lack NLRP3-driven resistance or who are not receiving PD-1–directed immunotherapy are less likely to benefit from this approach.
Why it matters
Potential benefit: If successful, this could make anti-PD-1 immunotherapies work for more patients by adding or targeting NLRP3 blockade.
How similar studies have performed: Preclinical studies, including animal models, have shown that blocking NLRP3 can improve anti-PD-1 responses, but clinical testing in people is still limited and largely novel.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Hanks, Brent Allen — Univ of North Carolina Chapel Hill
- Study coordinator: Hanks, Brent Allen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.